Hence, the development of a safe BBB-penetrating EP2 antagonist for clinical exploration is ongoing, and EP4 antagonists currently undergo clinical trials for cancer immunotherapy [17, 26, 44]. This evidence concerns the gene PTGER2 and cancer.